CNOOC Limited CEO
121.76 +121.76
Day range unavailable
52-week range unavailable
News
gurufocus.com Securities Fraud Class Action Lawsuit Pending Against Everest Group, Ltd.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline Everest Group, Ltd. ("Everest" or the "Company") (NYSE: [url="]EG[/url]) is the subject of a securities fraud class action lawsuit filed on behalf of investors
benzinga.com Global Markets Rejoice On US Stimulus Hopes Major global markets rose on Friday as U.S.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday 
benzinga.com Stocks That Hit 52-Week Lows On Thursday - benzinga.com Stocks That Hit 52-Week Lows On Wednesday
benzinga.com Stocks That Hit 52-Week Lows On Friday - benzinga.com Stocks That Hit 52-Week Lows On Friday
benzinga.com Stocks That Hit 52-Week Lows On Monday - benzinga.com Stocks Which Set New 52-Week High Yesterday, October 1st
- benzinga.com Stocks Which Set New 52-Week High Yesterday, September 13th
benzinga.com Stocks Which Set New 52-Week High Yesterday, September 12 - benzinga.com Oil & Gas Stock Roundup: Crude Extend Gains; Williams, Shell Unveil Large Deals - Analyst Blog
- benzinga.com 3 ADR ETFs Your Broker Forgot to Mention
benzinga.com Four ETFs For China's Soaring Oil Demand 
benzinga.com Benzinga's Top ETF Decliners, October 31st (RUSL, ERX, TMV, EDC) - benzinga.com Benzinga's Top ETF Decliners, September 8th (EDC, FAS, TNA, GLL)
- benzinga.com Benzinga's Top ETF Decliners (CZM, FDM, EDC, AGQ, UCO)
- benzinga.com Leading Analyst Firm Positions Sitecore in the Visionaries Quadrant in Web Content Management Magic Quadrant Report SAN FRANCISCO, CA--(Marketwire - August 10, 2009) - Sitecore, the leading provider of .NET Web Content Management System (CMS) software, today announced that the company was evaluated and positioned…
- benzinga.com Antisoma announces discontinuation of development of AS1402 LONDON and CAMBRIDGE, MA--(Marketwire - August 7, 2009) - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that the phase II trial of AS1402 in breast cancer is to be discontinued. This follows…